Treatment outcome in an <em>S</em>I model with evolutionary resistance: a Darwinian model for the evolution of resistance (Publications)
We consider a Darwinian (evolutionary game theoretic) version of a standard susceptible-infectious SI model in which the resistance of the disease causing pathogen to a treatment that prevents death t
Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART (Publications)
Although gut and lymph node (LN) memory CD4 T cells represent major HIV and simian immunodeficiency virus (SIV) tissue reservoirs, the study of the role of dendritic cells (DCs) in HIV persistence has
Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review (Publications)
OBJECTIVES: The slow progress of pharmacovigilance (PV) in low-income and middle-income countries (LMIC) raises questions about core challenges on the growth of PV, and the appropriateness of strategi
State of the science and future directions for research on HIV and cancer: summary of a joint workshop sponsored by IARC and NCI (Publications)
An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are drive
Anna K. H. Hirsch: drug design and optimisation to disarm dangerous germs (Publications)
Anna K. H. Hirsch, Professor and Head of the Department of Drug Design and Optimisation at the Helmholtz Institute for Pharmaceutical Research in Saarbrücken (HIPS), Germany, is dedicated to fighting
Jonathan L. Vennerstrom: I was standing on the shoulders of giants (Publications)
Jonathan L. Vennerstrom grew up in Ethiopia, where he was witness to the effects of leprosy and other infectious diseases of poverty on the local population. After his studies in organic chemistry, he
Kelly Chibale: learning to fail your way to success (Publications)
A portrait is given of Professor Kelly Chibale, the driving force behind H3D, the drug discovery and development centre at the University of Cape Town, South Africa. He is dedicated to the development
Basel: a hotspot for drug discovery and development against poverty-related diseases (Publications)
In discussion with Lukas Meier from the Swiss Tropical and Public Health Institute (Swiss TPH), Lutz Hegemann, Head of Novartis Global Health and Sustainability and Marcel Tanner, President of the Swi
Repurposing of tuberculosis drug candidates for the treatment of <em>Mycobacterium ulcerans</em> disease (Publications)
Buruli ulcer (BU) is a chronic necrotizing skin disease caused by Mycobacterium ulcerans. Historically, the disease was treated by surgical excision of the skin lesions, until an 8-week combination th
Quinacrine - the winding road from the most important antimalarial of its time to an indispensable antiparasitic (orphan) drug of our days (Publications)
Quinacrine, the main antimalarial drug during World War II, has had a chequered history that included the successful repurposing as an intrapleural sclerosant for the treatment of malignant pleural ef